BioNTech SE (NASDAQ:BNTX - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 1,330,327 shares were traded during trading, an increase of 43% from the previous session's volume of 930,600 shares.The stock last traded at $116.20 and had previously closed at $113.10.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on BNTX. Wall Street Zen lowered shares of BioNTech from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. Leerink Partners set a $112.00 price target on BioNTech in a research note on Monday. JPMorgan Chase & Co. dropped their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. BMO Capital Markets increased their target price on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Finally, Morgan Stanley dropped their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of "Moderate Buy" and an average target price of $138.25.
Read Our Latest Analysis on BNTX
BioNTech Stock Down 1.5%
The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average price of $98.89 and a two-hundred day moving average price of $108.34. The company has a market capitalization of $26.08 billion, a price-to-earnings ratio of -51.66 and a beta of 1.29.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm's revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.90 earnings per share. As a group, sell-side analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.
Institutional Trading of BioNTech
Several institutional investors and hedge funds have recently bought and sold shares of the stock. abrdn plc lifted its holdings in shares of BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock worth $43,947,000 after buying an additional 159,676 shares during the last quarter. Van ECK Associates Corp increased its stake in BioNTech by 25.1% in the fourth quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock valued at $13,493,000 after acquiring an additional 23,733 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in BioNTech during the fourth quarter valued at approximately $1,118,000. Vontobel Holding Ltd. raised its holdings in shares of BioNTech by 24.6% in the 4th quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company's stock worth $2,437,000 after buying an additional 4,227 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in BioNTech in the fourth quarter valued at $168,000. Institutional investors and hedge funds own 15.52% of the company's stock.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Read More
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
